AstraZeneca sees positives in latest roxadustat data
10th May 2019 07:29
(Sharecast News) - AstraZeneca announced top-line results from the pooled cardiovascular safety analyses of the global phase 3 programme for roxadustat on Friday, which its described as a first-in-class hypoxia-inducible-factor prolyl hydroxylase inhibitor.
Read moreDirector dealings: AstraZeneca CFO ups stake
8th May 2019 16:18
(Sharecast News) - AstraZeneca chief financial officer Marc Dunoyer purchased 8,500 ordinary shares in the FTSE 100-listed pharmaceuticals outfit on Tuesday.
Read moreAstraZeneca upbeat on latest results from potential breast cancer drug
8th May 2019 07:36
(Sharecast News) - AstraZeneca and its partner Daiichi Sankyo Company announced positive top-line results for the pivotal phase 2 'DESTINY-Breast01' trial of trastuzumab deruxtecan (DS-8201) on Wednesday.
Read moreAstraZeneca leukaemia drug trial reports positive results
7th May 2019 08:01
(Sharecast News) - AstraZeneca said a phase three trial of its Calquence treatment for chronic lymphocytic leukaemia had shown a "statistically-significant and clinically-meaningful improvement in progression-free survival" compared with a combination regimen.
Read moreAstraZeneca gets FDA approval for 'Qternmet XR'
3rd May 2019 07:27
(Sharecast News) - AstraZeneca announced on Friday that the US Food and Drug Administration (FDA) has approved 'Qternmet XR' (dapagliflozin, saxagliptin and metformin hydrochloride) extended release tablets as an oral adjunct treatment to diet and exercise, to improve glycaemic control in adults with type-2 diabetes (T2D).
Read moreTuesday broker round-up
30th Apr 2019 13:23
(Sharecast News) - Nexus: Numis downgrades to add with a target price of 165p.
Read moreMonday broker round-up
29th Apr 2019 13:25
(Sharecast News) - HomeServe: HSBC downgrades to reduce with a target price of 1,000p.
Read moreDeutsche stands by 'top pick' rating on AstraZeneca
29th Apr 2019 11:17
(Sharecast News) - Analysts at Deutsche Bank reiterated their 'buy' rating and 6,900p target price on British-Swedish pharmaceutical outfit AstraZeneca on Monday.
Read moreEU endorses wider use of AstraZeneca cancer drug
29th Apr 2019 07:30
(Sharecast News) - AstraZeneca's ovarian cancer drug Lynparza on Monday received an endorsement from the European Medicines Agency, where a committee approved it to be used as a first-line maintenance treatment.
Read moreAstraZeneca sees product sales rise 10pc in first quarter
26th Apr 2019 07:23
(Sharecast News) - AstraZeneca reported a 10% increase in its product sales in its first quarter on Friday, or 14% at constant exchange rates, to $5.47bn.
Read moreFriday preview: US Q1 GDP, RBS in focus
25th Apr 2019 14:44
(Sharecast News) - Barring surprises, the market spotlight at the end of the week will continue to be on the States, where the Department of Commerce is expected to publish a preliminary reading on first quarter GDP (consensus: 1.8%).
Read moreThursday broker round-up
11th Apr 2019 11:58
(Sharecast News) - Ocado: HSBC downgrades to reduce with a target price of 900p.
Read moreWednesday broker round-up
10th Apr 2019 13:02
(Sharecast News) - Glencore: RBC Capital Markets downgrades to sector perform with a target price of 330p.
Read moreAstraZeneca confirms new EU approval for 'Lynparza'
10th Apr 2019 07:29
(Sharecast News) - AstraZeneca and its partner Merck & Co announced on Wednesday that the European Commission has approved 'Lynparza' (olaparib) as a monotherapy for the treatment of adult patients with germline BRCA1 and 2-mutations (gBRCAm), and who have human epidermal growth factor receptor 2 (HER2)-negative locally-advanced or metastatic breast cancer.
Read moreFriday broker round-up
5th Apr 2019 12:53
(Sharecast News) - Purplebricks: Berenberg downgrades to sell with a target price of 80p.
Read more